Hyperion Therapeutics, developer of treatments for urea cycle disorders and illnesses, has brought in $60 million in a third round of financing from Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates and Sofinnova Ventures.
Based in South San Francisco, the company recently completed phase-two clinical trials for its lead drug candidate and says the new capital will be used to push it through phase three. This therapy is targeted at patients who are born without enough of a certain enzyme in their urea cycles, a condition that can lead to dangerously high levels of ammonia in the bloodstream.
Some of the money will also be used for a phase-two study looking at hepatic encephalopathy (a neurological disorder that occurs in patients with liver failure).
Hyperion previously raised a $40 million second round of venture funding and an undisclosed amount in a first round.